Clinical trials: Infection and Inflammatory Reaction
Severe Sepsis, Cardiac Arrest
Examination of the Impact of Better Surveillance and Communication of Patient Deterioration on Patient Related Outcomes
A hospitals manual method of patient monitoring will be implemented in an automated system and supported by an early patient deterioration detection for timely escalation.
- Conditions
- Severe Sepsis, Cardiac Arrest, Respiratory Failure
- Trial name
- NCT01692847
- Where
- United Kingdom
- Volunteers
- 678 people
- Sponsor
- Philips Healthcare
Candidiasis, Candidemia
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.
- Trial name
- NCT00105144
- Testing
- Micafungin, Caspofungin
- Where
- 167 sites in United States, Austria and 13 more
- Volunteers
- 611 people
- Sponsor
- Astellas Pharma Inc
Sepsis
Adult MDW Dual Cut-Off Accuracy Study
This study will establish the clinical performance of the Monocyte Distribution Width (MDW) parameter on the DxH 900/ DxH 690T hematology analyzers to aid in the detection and risk assessment of patients in the Emergency…
- Trial name
- MDW (NCT06885528)
- Testing
- Complete Blood Count with differential
- Where
- 5 sites in United States
- Volunteers
- 524 people
- Sponsor
- Beckman Coulter, Inc.
Skin Infections, Bacterial
ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)
This is an open label, multi-centre, non-interventional post-marketing surveillance.
- Trial name
- ALTARGOPMS (NCT01445600)
- Testing
- ALTARGO(retapamulin)
- Where
- South Korea
- Volunteers
- 3,612 people
- Sponsor
- GlaxoSmithKline
Sars-CoV2
Rhu-pGSN for Severe Covid-19 Pneumonia
Study Objectives: Primary To assess the efficacy (survival without organ failure on Day 14) of three doses of rhu-pGSN administered intravenously (IV) plus standard of care (SOC) to hospitalized subjects with a primary diagnosis…
- Trial name
- NCT04358406
- Testing
- Recombinant human plasma gelsolin (Rhu-pGSN)
- Where
- 3 sites in Romania, Spain
- Volunteers
- 64 people
- Sponsor
- BioAegis Therapeutics Inc.
Oral Dysbiosis
Effects of a Composition on the Oral Microbiome, pH, Nitrite/Nitrate Ratio, Elastases and Inflammation in Oral Dysbiosis
Dysbiosis is a condition in which the normal function of an ecological net is altered. In dysbiosis a state of inflammation, a loss of hydration, a change in pH, a loss of the barrier function are all allies of key pathogens that…
- Trial name
- NCT05463484
- Testing
- Test composition Saliactive® (olive product, betaine and xylitol), Control
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Mucosa Innovations, S.L.
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Candidiasis
Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis
The study will evaluate how effective and how safe the drug micafungin is when compared to the drug amphotericin B deoxycholate in treating neonates and young infants with certain fungal infections.
- Trial name
- MAGIC-2 (NCT00815516)
- Testing
- micafungin, amphotericin B deoxycholate
- Where
- 17 sites in United States, Brazil and 10 more
- Volunteers
- 30 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Coronavirus Infection, Cytokine Storm
Yoga Pranayama Adjuvant to Treat Burden COVID-19
COronaVIrus Disease or Severe Acute Respiratory Syndrome -CoV-2 or COVID-19, mortality occurs mainly from immunological behavior or by suicide after healing .
- Conditions
- Coronavirus Infection, Cytokine Storm, Mental Disorder
- Trial name
- YOCO (NCT04413747)
- Testing
- morning Yoga-based breathing support, pre_lunch Yoga-based breathing support, pre_dinner Yoga-based breathing support
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Health Ricerca e Sviluppo S.R.L.
Septic Shock, Endotoxemia
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
- Trial name
- TIGRIS (NCT03901807)
- Testing
- Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
- Where
- 20 sites in United States
- Volunteers
- 157 people
- Sponsor
- Spectral Diagnostics (US) Inc.
Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in…
- Conditions
- Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE, Complicated Urinary Tract Infection (cUTI) Due to CRE
- Trial name
- CARE (NCT01970371)
- Testing
- plazomicin, colistin, meropenem
- Volunteers
- 69 people
- Sponsor
- Achaogen, Inc.
Severe COVID-19 Disease
RAPA-501-Allo Therapy of COVID-19-ARDS
The first-in-human Phase 1 study component will evaluate two dose levels of RAPA-501-ALLO off the shelf cells in patients with COVID-19-related ARDS, with key endpoints of safety, biologic and potential disease-modifying effects.
- Trial name
- NCT04482699
- Testing
- RAPA-501-Allo off-the-shelf Therapy of COVID-19
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rapa Therapeutics LLC
Severe Sepsis
Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up
Subjects previously enrolled / randomized in the ReActIF-ICE (Recovery from acute immune failure in septic shock by immune cell extracorporeal terapy - immune competence enhancement) study received either standard sepsis…
- Trial name
- ReActIF- LTO (NCT06143137)
- Where
- 2 sites in Germany
- Volunteers
- 142 people
- Sponsor
- Artcline GmbH
Sepsis
CLEAR Sepsis Clinical Study
To investigate the relationship between initial ClearSight™ derived hemodynamic parameters and outcomes (death, ongoing organ dysfunction or delayed ICU admission) in patients with acute infection and possible sepsis, with a…
- Trial name
- CLEAR Sepsis (NCT03231956)
- Testing
- ClearSight™ / EV1000NI Clinical Platform
- Where
- 5 sites in United States
- Volunteers
- 182 people
- Sponsor
- Edwards Lifesciences
Bronchopulmonary Dysplasia
Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants
The phase 1/2 trial aims to evaluate the safety and efficacy of EXOB-001 consisting of extracellular vesicles derived from umbilical cord mesenchymal stromal cells in the prevention of bronchopulmonary dysplasia (BPD) in…
- Trial name
- EVENEW (NCT06279741)
- Testing
- Endotracheopulmonary Instillation, Suspension
- Where
- 8 sites in Belgium, Italy
- Volunteers
- 265 people
- Sponsor
- EXO Biologics S.A.
Gingivitis
Dose-Response Study of Iocide Oral Rinse
The purpose of this study is to explore the dose-response relationship of Iocide oral rinse in a clinical trial of gingivitis. Approximately sixty (60) otherwise healthy subjects having gingivitis will be randomized into the…
- Trial name
- NCT01103102
- Testing
- Iocide Oral Rinse
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Biomedical Development Corporation
Sepsis, Acute Kidney Injury
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within…
- Trial name
- SERENIA (NCT07215702)
- Testing
- AZD4144
- Where
- 74 sites in United States, Argentina and 12 more
- Volunteers
- 124 people
- Sponsor
- AstraZeneca
Skin Infection
A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections
In this study, a multicenter, randomized, double-blind, placebo-controlled trial design is used to evaluate the efficacy and safety of two doses of 9MW1411 injection in patients with ABSSSI caused by S. aureus.
- Trial name
- NCT05339802
- Testing
- 9MW1411 injection 1 combined with Linezolid, 9MW1411 injection 2 combined with Linezolid
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
- Trial name
- NCT02924402
- Testing
- XmAb13676
- Where
- 23 sites in United States, France and 2 more
- Volunteers
- 154 people
- Sponsor
- Xencor, Inc.